ZOLMITRIPTAN-ODT TABLET (ORALLY DISINTEGRATING)

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

ZOLMITRIPTAN

Beschikbaar vanaf:

JUBILANT GENERICS LIMITED

ATC-code:

N02CC03

INN (Algemene Internationale Benaming):

ZOLMITRIPTAN

Dosering:

2.5MG

farmaceutische vorm:

TABLET (ORALLY DISINTEGRATING)

Samenstelling:

ZOLMITRIPTAN 2.5MG

Toedieningsweg:

ORAL

Eenheden in pakket:

6

Prescription-type:

Prescription

Therapeutisch gebied:

SELECTIVE SEROTONIN AGONISTS

Product samenvatting:

Active ingredient group (AIG) number: 0134381001; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2014-01-20

Productkenmerken

_ZOLMITRIPTAN-ODT _
_Page 1 of 31 _
PRODUCT MONOGRAPH
PR
ZOLMITRIPTAN-ODT
Zolmitriptan Orally Disintegrating Tablets
2.5 mg
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
SPONSOR: DATE OF REVISION:
Jubilant Generics Limited
April 1, 2020
1A- Sector 16A, Institutional Area,
Noida, Uttar Pradesh, India, 201301
DISTRIBUTOR:
Pharmapar Inc.,
1565 Boul. Lionel- Boulet, Varennes QC
J3X 1P7
SUBMISSION CONTROL NO.: 237423
_ZOLMITRIPTAN-ODT _
_Page 2 of 31 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................. 3
SUMMARY PRODUCT
INFORMATION.....................................................................
3
INDICATIONS AND CLINICAL
USE............................................................................
3
CONTRAINDICATIONS..................................................................................................
3
WARNINGS AND
PRECAUTIONS................................................................................
4
ADVERSE
REACTIONS..................................................................................................
10
DRUG
INTERACTIONS..................................................................................................
15
DOSAGE AND
ADMINISTRATION..............................................................................
17
OVERDOSAGE.................................................................................................................
18
ACTION AND CLINICAL
PHARMACOLOGY.............................................................
18
STORAGE AND
STABILITY..........................................................................................
20
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................. 20
PART II: SCIENTIFIC
INFORMATION.........................................................................
21
PHARMACEUTICAL
INFORMATION..........................................................................
21
CLINICAL
TRIALS..............................................................